If you’ve ever wondered why a generic medicine costs ₹20 in one pharmacy and ₹80 in another—or why the government can (or cannot) cap what pharma companies charge—you’re looking at the intersection of India’s drug price control system. This guide breaks down the key players, the rules, and what they mean for buyers of Indian generic medicines.
🏛️ What Is the NPPA?
The National Pharmaceutical Pricing Authority (NPPA) is India’s primary regulator for drug prices. Established in 1997 under the Ministry of Chemicals and Fertilizers, the NPPA administers the Drug Price Control Order (DPCO), a legal framework that sets ceiling prices on certain essential medicines.
The NPPA’s mandate is straightforward: ensure that essential medicines remain affordable for the Indian population while allowing manufacturers enough room to cover costs and invest in quality. In practice, this means the NPPA periodically revises ceiling prices based on Wholesale Price Index (WPI) inflation and other factors.
As of July 2026, the NPPA had fixed retail prices for 3,845 new medicines since its establishment, according to government data cited by multiple news outlets (as reported by Morung Express, July 28, 2026).
📋 The NLEM: Which Drugs Are Price-Controlled?
Not every drug sold in India falls under price control. The NPPA regulates only those on the National List of Essential Medicines (NLEM)—a government-published list of medicines deemed essential for public health.
The NLEM is periodically revised to reflect changing disease patterns, new treatments, and public health priorities. When a drug is added to the NLEM, its price becomes subject to DPCO regulation. When it’s removed, price caps no longer apply.
Here’s the critical reality: approximately 8 out of 10 medicines sold in India are outside government price control, according to a parliamentary panel report covered by The South First (August 9, 2026). This means the vast majority of drugs on the Indian market—including many generics, branded formulations, and newer therapies—can be priced freely by manufacturers.
- Schedule I drugs (on the NLEM): Subject to ceiling price regulation under DPCO
- Non-Schedule I drugs: Free pricing — manufacturers set their own MRP
- Generic versions of Schedule I drugs: Also subject to ceiling prices, but the ceiling is calculated based on the average price of the top 3-5 brands
💰 How Does the NPPA Calculate Ceiling Prices?
The DPCO formula for ceiling prices on NLEM drugs is based on a simple but powerful principle: the ceiling price is set at the average price of the top 3-5 brands (by market share) of that drug, plus a manufacturing cost component. The exact formula has evolved across DPCO revisions (1994, 2002, 2013, 2019).
When the NPPA revises ceiling prices, it typically factors in:
- Wholesale Price Index (WPI) inflation — the official inflation measure for wholesale goods
- Manufacturing cost changes — raw materials, energy, labor
- Currency fluctuation impact — especially for imported active pharmaceutical ingredients (APIs)
- Policy objectives — balancing access vs. sustainability for manufacturers
For example, in March 2026, the NPPA allowed a 0.64% price increase on essential medicines, tracking the WPI rise (as reported by Business Standard, March 25, 2026). This small adjustment reflects the NPPA’s careful calibration: allowing manufacturers to recover rising costs without burdening consumers with large price hikes.
On the other end of the spectrum, in May 2026, the NPPA imposed price caps on 30 new drugs (as reported by Financial Express, May 31, 2026), bringing them under DPCO regulation for the first time. This demonstrates the NPPA’s ongoing expansion of price control coverage.
🏥 Cancer Drugs and the Expanding Price Control Net
One of the most significant recent developments in India’s drug pricing landscape is the expansion of price control to oncology products. As of February 2026, the government confirmed that all cancer drugs are regulated under the DPCO, with 131 formulations price-capped (as reported by Medical Dialogues, February 15, 2026).
This is a major shift. Cancer medicines have historically been among the most expensive and least accessible treatments in India, with many patients forced to pay out-of-pocket for therapies that can cost lakhs of rupees per cycle. By bringing these drugs under price ceilings, the government aims to make life-saving oncology treatments more affordable.
However, the parliamentary panel report from July 2026 (covered by The Indian Awaaz, July 27, 2026) called for a broader review, flagging that the current framework leaves most medicines outside control and recommending that price caps be extended further. This ongoing policy debate directly affects how quickly and comprehensively the NPPA’s net expands.
📊 What Does This Mean for Generic Medicine Buyers?
For buyers of Indian generic medicines—whether patients, pharmacies, or international buyers—the drug price control system has several practical implications:
- Price-controlled (NLEM) generics: Government-set ceiling prices provide a predictable floor and ceiling, but prices can still vary across pharmacies due to distribution margins, stockist discounts, and local market conditions.
- Non-NLEM generics: These are free-market products. Prices vary widely based on brand positioning, manufacturing quality, and distribution. This is where comparing multiple suppliers pays off.
- International buyers: Drugs exported from India that are price-controlled domestically may show different pricing in export markets, since DPCO ceilings apply to the Indian domestic market, not export prices.
For buyers looking to verify quality and navigate the Indian generic medicine market safely, refer to IMSDA’s verified member directory for a list of trusted pharmaceutical distributors.
🔮 What’s Next for India’s Drug Pricing System?
The drug pricing landscape in India is in active flux. Several signals point to continued evolution:
- Parliamentary pressure for broader coverage: The July 2026 panel report explicitly called for extending price caps beyond the current NLEM net, potentially bringing 80% of currently uncontrolled medicines under regulation.
- More drugs added to NLEM: The government reported Rs 3,788 crore in savings from existing price controls (Medical Dialogues, March 24, 2025) and hinted at expanding the list further.
- Digital and transparency reforms: Alongside drug price regulation, India is pursuing broader regulatory modernization (including the CDSCO’s digital drug platform) that could improve price transparency and reduce information asymmetry for buyers.
- Oncology expansion: With all cancer drugs now under DPCO, the next frontier may be other high-cost therapeutic categories like biologics and specialty drugs.
For now, the most actionable takeaway for buyers is simple: know whether the medicine you’re purchasing is on the NLEM. If it is, government ceilings provide a benchmark—but market prices still vary. If it’s not, compare prices across suppliers, verify quality credentials, and avoid paying a premium for a generic that should be affordable.
Disclaimer: Drug price regulations change. Always verify the current NLEM status and NPPA ceiling prices through official government sources before making purchasing decisions based on capped prices.
For more information, contact IMSDA at contact@indiamedicine.org.